Now FDA hottest Oncology: Larotrectinib(LOXO105) & 2nd G ---LOXO195 2097002-61-2, we are TOP supplier.
Why my LOXO195 2097002-61-2, assay is more than 99.5%, Single impurity less than 0.1%, because LOXO195 2097002-61-2 our batch size is 1kg, price is world best.
LOXO195 2097002-61-2. Batch size 1-10kg. HPLC 99%.
Larotrectinib(LOXO105) & Intermediates, we could Batch size 10-100kg supply.
LOXO195 2097002-61-2 is a potent and selective TRK inhibitor capable of addressing potential mechanisms of acquired resistance that may emerge in patients receiving larotrectinib (LOXO-101) or multikinase inhibitors with anti-TRK activity. LOXO-195 demonstrated potent inhibition of TRK fusions, including critical acquired resistance mutations, in enzyme and cellular assays, with minimal activity against other kinases. In diverse TRK fusion mouse models, LOXO-195 inhibited phospho-ERK and caused dramatic tumor growth inhibition, superior to first generation TRK inhibitors, without significant toxicity.
Name: LOXO-195
CAS#: 2097002-61-2
Chemical Formula: C20H21FN6O
Exact Mass: 380.1761
Molecular Weight: 380.4274
Elemental Analysis: C, 63.14; H, 5.56; F, 4.99; N, 22.09; O, 4.21
Related CAS #: 2097002-61-2 2097002-59-8 (RS-isomer) 1350884-56-8 (R racemic)
Synonym: LOXO-195; LOXO 195; LOXO195.
IUPAC/Chemical Name: (13E,14E,22R,6R)-35-fluoro-6-methyl-7-aza-1(5,3)-pyrazolo[1,5-a]pyrimidina-3(3,2)-pyridina-2(1,2)-pyrrolidinacyclooctaphan-8-one
InChi Key: OEBIHOVSAMBXIB-SJKOYZFVSA-N
InChi Code: InChI=1S/C20H21FN6O/c1-12-4-5-16-14(9-13(21)10-22-16)17-3-2-7-26(17)18-6-8-27-19(25-18)15(11-23-27)20(28)24-12/h6,8-12,17H,2-5,7H2,1H3,(H,24,28)/t12-,17-/m1/s1
SMILES Code: FC1=CN=C(CC[C@@H](C)NC(C2=C3N(C=CC4=N3)N=C2)=O)C([C@@H]5N4CCC5)=C1
Why my LOXO195 2097002-61-2, assay is more than 99.5%, Single impurity less than 0.1%, because LOXO195 2097002-61-2 our batch size is 1kg, price is world best.
LOXO195 2097002-61-2. Batch size 1-10kg. HPLC 99%.
Larotrectinib(LOXO105) & Intermediates, we could Batch size 10-100kg supply.
We have already carried out LOXO195 2097002-61-2 batch production, also have completed the development of quality standards and process validation. The stable process is the guarantee of product quality. For LOXO195 2097002-61-2 , we use HPLC-UV detection instead of other companies' HPLC-ELSD test, Our detection method is more sensitive.
LOXO195 2097002-61-2 is a potent and selective TRK inhibitor capable of addressing potential mechanisms of acquired resistance that may emerge in patients receiving larotrectinib (LOXO-101) or multikinase inhibitors with anti-TRK activity. LOXO-195 demonstrated potent inhibition of TRK fusions, including critical acquired resistance mutations, in enzyme and cellular assays, with minimal activity against other kinases. In diverse TRK fusion mouse models, LOXO-195 inhibited phospho-ERK and caused dramatic tumor growth inhibition, superior to first generation TRK inhibitors, without significant toxicity.
Name: LOXO-195
CAS#: 2097002-61-2
Chemical Formula: C20H21FN6O
Exact Mass: 380.1761
Molecular Weight: 380.4274
Elemental Analysis: C, 63.14; H, 5.56; F, 4.99; N, 22.09; O, 4.21
Related CAS #: 2097002-61-2 2097002-59-8 (RS-isomer) 1350884-56-8 (R racemic)
Synonym: LOXO-195; LOXO 195; LOXO195.
FDA New, GMP Do
Clinical Phase II, III Intermediates
GMP Custom synthesis, Full Document
R&D Center: 8000 sq, More than 100 hoods
Pilot Plant: 20000sq, 40 reactors from 5-200L
Manufacturing Site: 800000sq, 40 reactors from 100-5000L
IUPAC/Chemical Name: (13E,14E,22R,6R)-35-fluoro-6-methyl-7-aza-1(5,3)-pyrazolo[1,5-a]pyrimidina-3(3,2)-pyridina-2(1,2)-pyrrolidinacyclooctaphan-8-one
InChi Key: OEBIHOVSAMBXIB-SJKOYZFVSA-N
InChi Code: InChI=1S/C20H21FN6O/c1-12-4-5-16-14(9-13(21)10-22-16)17-3-2-7-26(17)18-6-8-27-19(25-18)15(11-23-27)20(28)24-12/h6,8-12,17H,2-5,7H2,1H3,(H,24,28)/t12-,17-/m1/s1
SMILES Code: FC1=CN=C(CC[C@@H](C)NC(C2=C3N(C=CC4=N3)N=C2)=O)C([C@@H]5N4CCC5)=C1
